Covishield shows better antibody response than Covaxin, says study

0
9



Indian health care workers who were administered Covishield have shown better antibody response than the Covaxin recipients, revealed a recent study.


The study, published in an online archive for unpublished manuscripts in medical sciences medRxiv, showed that after two shots of the vaccines, 98 per cent recipients of Covishield showed antibody response, while the same was once 80 per cent among Covaxin recipients.


The study published by a group of doctors – Awadhesh Kumar Singh, Sanjeev Ratnakar Phatak, Ritu Singh, Kingshuk Bhattacharjee, Nagendra Kumar Singh, Arvind Gupta, and Arvind Sharma – has not been peer-reviewed yet. The researchers have declared no competing interest and that no underwriting was once received for this cross-sectional study.


The study was once aimed at analysing the antibody response after two total doses of Covishield and Covaxin in Indians.


“We assessed the humoral immune response after the completion of two doses of both ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) vaccines in Indian health care workers,” the authors said.


ALSO READ: Centre provides over 24.60 crore COVID vaccine doses to States, UTs



A pan-Indian cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study was once conducted that measured Sars-CoV-2 anti-spike binding antibody quantitatively 21 days or more after the first and second dose of two vaccines in both Sars-CoV-2 naïve and retrieved health care workers.


A few of the 515 health care workers (305 male and 210 female), 95 per cent showed seropositivity after two doses of both vaccines. Of the 425 Covishield recipients, 98.1 per cent showed seropositivity, and of the 90 Covaxin recipients, 80 per cent showed seropositivity.


Seropositivity means having the presence of antibodies in the blood serum.


Experts felt that antibody developed or not developed is a binary variable. What must be examined is the difference between intent or median titre between the two groups.








Samiran Panda, head of epidemiology and communicable division at the Indian Council of Medical Research, which is a co-developer of Covaxin, told Trade Standard, “Antibody developed or not developed is a binary variable (above a predefined laboratory cut-off). Then again, what’s the result from a quantitative comparison – also must be examined – is the difference between the intent or median titre between the two groups.”


He further added that these comparisons allow for population level inference (not for any specific individual), given the pattern of participants in the study is drawn randomly from the complete population of interest.


“Any arbitrary draw of a pattern brings in a bias and does not allow extrapolation of inference on a larger universe of people,” said Panda.


ALSO READ: Rahul Gandhi slams Centre for fighting for blue tick amid vaccine scarcity



In addition,immunity isn’t just guided by the humoral arm of immunity but also the cellular arm, he explained.


“In spite of everything, it must also be appreciated that immunity is guided not only by the humoral arm of the immunity (decided by neutralising antibody titres, etc) following vaccination, but also by the cellular arm, which determines immune reminiscence,” he said.


The researchers said the primary aim was once to analyse the antibody response (seropositivity and median antibody titre) following each and every dose of both vaccines and its correlation to age, sex, blood group, body mass index (BMI), and comorbidities.


“While no difference was once observed relating to sex, BMI, blood group, and any comorbidities, people above 60 years or those with Kind 2 diabetes had significantly lower seropositivity rates,” the authors said.


Both vaccine recipients had similar solicited gentle to moderate adverse events and none had severe or unsolicited side effects.


“Both vaccines elicited good immune response after two doses, even though seropositivity rates and median anti-spike antibody titre was once significantly higher in Covishield, in comparison to Covaxin arm,” they concluded.


This is, on the other hand, not an efficacy analysis of both the vaccines. Efficacy analysis would intent if those vaccinated get symptomatic Covid or not.

Top stories / News / Trade

LEAVE A REPLY

Please enter your comment!
Please enter your name here